PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
176.45 - 178.59
86.62 - 184.48
124.91M / 173.95M (Avg.)
50.81 | 3.50
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
5.66%
Revenue growth above 1.5x AVGO's 2.49%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
8.42%
Gross profit growth above 1.5x AVGO's 2.96%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
12.38%
EBIT growth above 1.5x AVGO's 3.79%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
12.38%
Operating income growth above 1.5x AVGO's 3.79%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
12.09%
Net income growth above 1.5x AVGO's 7.20%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
8.62%
EPS growth similar to AVGO's 7.84%. Walter Schloss would assume both have parallel share structures and profit trends.
14.55%
Diluted EPS growth above 1.5x AVGO's 8.00%. David Dodd would see if there's a robust moat protecting these shareholder gains.
1.10%
Slight or no buybacks while AVGO is reducing shares. John Neff might see a missed opportunity if the company’s stock is cheap.
0.07%
Diluted share change of 0.07% while AVGO is zero. Bruce Berkowitz might see a minor difference that could widen over time.
No Data
No Data available this quarter, please select a different quarter.
-52.37%
Negative OCF growth while AVGO is at 51.80%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-58.37%
Negative FCF growth while AVGO is at 68.48%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
176.31%
10Y revenue/share CAGR above 1.5x AVGO's 55.71%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
29.17%
5Y revenue/share CAGR at 50-75% of AVGO's 55.71%. Martin Whitman would worry about a lagging mid-term growth trajectory.
5.18%
3Y revenue/share CAGR under 50% of AVGO's 55.71%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
-0.16%
Negative 10Y OCF/share CAGR while AVGO stands at 180.39%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
321.47%
5Y OCF/share CAGR above 1.5x AVGO's 180.39%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
-6.42%
Negative 3Y OCF/share CAGR while AVGO stands at 180.39%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
219.36%
Below 50% of AVGO's 479.11%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
52.64%
Below 50% of AVGO's 479.11%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
215.77%
Below 50% of AVGO's 479.11%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
394.74%
10Y equity/share CAGR above 1.5x AVGO's 150.73%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
94.82%
5Y equity/share CAGR at 50-75% of AVGO's 150.73%. Martin Whitman would question a shortfall in capital accumulation vs. the competitor.
27.97%
Below 50% of AVGO's 150.73%. Michael Burry suspects a serious short-term disadvantage in building book value.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
22.36%
Our AR growth while AVGO is cutting. John Neff questions if the competitor outperforms in collections or if we’re pushing credit to maintain sales.
-5.00%
Inventory is declining while AVGO stands at 12.95%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
3.73%
Asset growth at 50-75% of AVGO's 6.83%. Martin Whitman questions if the firm is lagging expansions or if the competitor invests more aggressively.
5.85%
75-90% of AVGO's 6.66%. Bill Ackman advocates improvements in profitability or buybacks to keep pace in net worth growth.
-2.02%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
7.00%
R&D growth drastically higher vs. AVGO's 2.44%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
5.52%
SG&A growth well above AVGO's 2.00%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.